[89Zr]atezolizumab is a PET tracer that binds to programmed cell death ligand-1 (PD-L1), which is a key immune checkpoint expressed on a variety of human tumour types and immune cells and is an established target in cancer immunotherapy [1]. The gene discussed is CD274; the disease is cancer.